참고문헌 (43)

1. Mol. Pharm. Remenar 11 1739 2014 10.1021/mp500070m Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics 

   상세보기

2. Eur. J. Pharm. Biopharm. Goke 2017 Novel strategies for the formulation and processing of poorly water-soluble drugs 

3. Int. J. Nanomed. Junghann 3 295 2008 Nanocrystal technology, drug delivery and clinical applications 

   상세보기

4. Int. J. Pharm. Van Eerdenbrugh 364 64 2008 10.1016/j.ijpharm.2008.07.023 Topdown production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products 

   상세보기

5. Clin. Pharmacokinet. Samtani 48 585 2009 10.2165/11316870-000000000-00000 Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia 

   상세보기

6. Schizophr. Res. Turncliff 159 404 2014 10.1016/j.schres.2014.09.021 Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia 

   상세보기

7. Eur. J. Pharm. Biopharm. Mittapelly 101 62 2016 10.1016/j.ejpb.2016.01.003 Investigation of salt formation between memantine and pamoic acid: Its exploitation in nanocrystalline form as long acting injection 

   상세보기

8. J. Pharm. Sci. Liederer 95 1177 2006 10.1002/jps.20542 Enzymes involved in the bioconversion of ester-based prodrugs 

   상세보기

9. Clin. Ther. Matthews 28 184 2006 10.1016/j.clinthera.2006.02.012 Entecavir for the treatment of chronic hepatitis B virus infection 

   상세보기

10. Hepatology Lok 50 661 2009 10.1002/hep.23190 Chronic hepatitis B: update 2009 

    상세보기

11. Hepatology Chang 52 886 2010 10.1002/hep.23785 Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B 

    상세보기

12. Entecavir pharmacology review. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21797_21798_BaracludeTOC.cfm. 

13. Int. J. Pharm. Ho 543 52 2018 10.1016/j.ijpharm.2018.03.042 Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery 

    상세보기

14. Pharm. World Sci. Kadir 15 173 1993 10.1007/BF01880562 Intramuscular and subcutaneous drug delivery: encapsulation in liposomes and other methods to manipulate drug availability 

    상세보기

15. Adv. Drug Deliv. Rev. Medlicott 56 1345 2004 10.1016/j.addr.2004.02.005 Sustained release veterinary parenteral products 

    상세보기

16. Int. J. Pharm. Zuidema 105 189 1994 10.1016/0378-5173(94)90103-1 Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II) 

    상세보기

17. Pharm. Res. Champion 25 1815 2008 10.1007/s11095-008-9562-y Role of particle size in phagocytosis of polymeric microspheres 

    상세보기

18. PLoS One Kusaka 9 e92634 2014 10.1371/journal.pone.0092634 Effect of silica particle size on macrophage inflammatory responses 

    상세보기

19. J. Control. Release Darville 230 95 2016 10.1016/j.jconrel.2016.03.041 The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension 

    상세보기

20. Semin. Immunol. Anderson 20 86 2008 10.1016/j.smim.2007.11.004 Foreign body reaction to biomaterials 

    상세보기

21. Haddad 2011 Antipsychotic Long-acting Injections 

22. Invega Sustenna® pharmacological review; 2010. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022264s000pharmr.pdf. 

23. Drug Deliv. Zhao 21 467 2014 10.3109/10717544.2014.881438 Preparation and characterization of betulin nanoparticles for oral hypoglycemic drug by antisolvent precipitation 

    상세보기

24. J. Biomed. Nanotechnol. Kuntsche 5 384 2009 10.1166/jbn.2009.1047 Size determinations of colloidal fat emulsions: a comparative study 

    상세보기

25. Langmuir Matteucci 22 8951 2006 10.1021/la061122t Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization 

    상세보기

26. J.W. Kostanski, T. Matsuda, M. Nerurkar, V.H. Naringrekar, Controlled release sterile injectable aripiprazole formulation and method, 2007, US8030313. 

27. Spine J. Tiso 4 468 2004 10.1016/j.spinee.2003.10.007 Adverse central nervous system sequelae after selective transforaminal block: the role of corticosteroids 

    상세보기

28. G. Malhotra, S. Singh, K.A. Ansari, Paliperidone palmitate particles and compositions thereof, 2016, WO2016199170. 

29. Pharm. Res. Paquette 31 2065 2014 10.1007/s11095-014-1308-4 Long-acting atypical antipsychotics: characterization of the local tissue response 

    상세보기

30. Arch. Histol. Cytol. Kawamata 66 273 2003 10.1679/aohc.66.273 Structure of the rat subcutaneous connective tissue in relation to its sliding mechanism 

    상세보기

31. Expert Opin. Drug Deliv. Frost 4 427 2007 10.1517/17425247.4.4.427 Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration 

    상세보기

32. Curr. Opin. Mol. Ther. McDonald 12 461 2010 Subcutaneous administration of biotherapeutics: current experience in animal models 

    상세보기

33. Comp. Biochem. Physiol. A Rendell 106 349 1993 10.1016/0300-9629(93)90524-8 Skin blood flow in the wistar-kyoto rat and the spontaneously hypertensive rat 

    상세보기

34. Xenobiotica Moss 45 60 2015 10.3109/00498254.2014.942409 The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys 

    상세보기

35. J. Pharm. Sci. Darville 103 2072 2014 10.1002/jps.24014 Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats 

    상세보기

36. Center for Drug Evaluation and Research (CDER), Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, 2005. 

37. Invega sustenna® product information, 2010. Available at: http://www.janssen.com/australia/sites/www_janssen_com_australia/files/prod_files/live/invega_sustenna_pi.pdf. 

38. Drug Res. Huang 63 644 2013 10.1055/s-0033-1358665 A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs 

    상세보기

39. Eur. J. Pharm. Biopharm. Baert 72 502 2009 10.1016/j.ejpb.2009.03.006 Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment 

    상세보기

40. Toxicol. Pathol. Darville 44 189 2015 10.1177/0192623315618291 Modeling the time course of the tissue responses to intramuscular long acting paliperidone palmitate nano-/microcrystals and polystyrene microspheres in the rat 

    상세보기

41. Biophys. J. Simon 53 163 1988 10.1016/S0006-3495(88)83078-9 Biophysical aspects of microsphere engulfment by human-neutrophils 

    상세보기

42. European Medicines Agency assessment report of Baraclude® tablet, 2014. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000623/human_med_000670.jsp&mid=WC0b01ac058001d124. 

43. Lancet Margolis 390 1499 2017 10.1016/S0140-6736(17)31917-7 Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial 

    상세보기